Preliminary safety data of the EORTC 10994/BIG 00-01 neoadjuvant trial comparing 3 cycles of docetaxel followed by 3 cycles of epirubicin-docetaxel versus 6 cycles of FEC 100 in patients with locally advanced/inflammatory or large operable breast cancer.

被引：0
|
作者：
Karina, M.
Bogaerts, J.
Piccart, M.
Mauriac, L.
Campone, M.
Tubiana-Hulin, M.
Petit, T.
Rouanet, P.
Jassem, J.
Cufer, T.
Blot, E.
Abadie-Lacourtoisie, S.
Zaman, K.
Amaral, N.
Cameron, D.
Bergh, J.
Bonnefoi, H.
机构：
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S146 / S147
页数：2
相关论文
共 8 条
  • [1] Safety analysis of the PACS 01 adjuvant trial comparing 6 cycles of FEC 100 to 3 cycles of FEC 100 followed by 3 cycles of docetaxel Taxotere® for node positive breast cancer
    Roche, H
    Spielmann, M
    Fumoleau, P
    Canon, JL
    Bravo, P
    Orfreuvre, H
    Piot, G
    Kerbrat, P
    Serin, D
    Viens, P
    Geneve, J
    Asselain, B
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S32 - S32
  • [2] Five years analysis of the PACS 01 trial:: 6 cycles of FEC100 vs 3 cycles of FECI00 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer
    Roché, H
    Fumoleau, P
    Spielmann, M
    Canon, JL
    Delozier, T
    Kerbrat, P
    Serin, D
    Lortholary, A
    de Ghislain, C
    Viens, P
    Bergerat, JP
    Genève, J
    Martin, AL
    Asselain, B
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S16
  • [3] A randomized phase Ill trial of neoadjuvant sequential chemotherapy with 4 cycles of adriamycin plus cyclophosphamide followed by 4 cycles of docetaxel (AC4-D4) versus shorter 3 cycles of FEC followed by 3 cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-Shorter): First report of efficacy & toxicity profile
    Kim, J. E.
    Ahn, J-H
    Jung, K. H.
    Lee, H. J.
    Gong, G-Y
    Lee, E-M
    Ha, E. J.
    Son, B-H
    Ahn, S-H
    Ahn, S. D.
    Kim, H-H
    Shin, H. J.
    Kim, S-B
    [J]. CANCER RESEARCH, 2016, 76
  • [4] Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
    Inhwan Hwang
    Jeong Eun Kim
    Jae Ho Jeong
    Jin-Hee Ahn
    Kyung Hae Jung
    Byung Ho Son
    Hak Hee Kim
    Junyoung Shin
    Hee Jin Lee
    Gyungyub Gong
    Sung-Bae Kim
    [J]. Breast Cancer Research and Treatment, 2023, 201 : 193 - 204
  • [5] Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
    Hwang, Inhwan
    Kim, Jeong Eun
    Jeong, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Son, Byung Ho
    Kim, Hak Hee
    Shin, Junyoung
    Lee, Hee Jin
    Gong, Gyungyub
    Kim, Sung-Bae
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 193 - 204
  • [6] Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer
    Reitsamer, R
    Peintinger, F
    Prokop, E
    Hitzl, W
    [J]. ANTI-CANCER DRUGS, 2005, 16 (08) : 867 - 870
  • [7] Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer (vol 16, pg 867, 2005)
    Reitsamer, R.
    Peintinger, F.
    Prokop, E.
    Hitzl, W.
    [J]. ANTI-CANCER DRUGS, 2006, 17 (03) : 363 - 363
  • [8] Safety analysis from PACS 04 -: A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients:: Preliminary results.
    Spielmann, M.
    Roché, H.
    Delozier, T.
    Romieu, G.
    Bourgeois, H.
    Serin, D.
    Canon, J.
    Asselain, B.
    Roca, L.
    Genève, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 35S - 35S
1